LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Hereditary Diffuse Leukoencephalopathy with Spheroids: Diffusion Restriction on Magnetic Resonance Imaging and Novel Mutation in an Indian Patient.

    Manjunath, Varun / Nadaf, Swaleha / Chakor, Rahul T / Bolegave, Vyankatesh

    Annals of Indian Academy of Neurology

    2021  Volume 25, Issue 2, Page(s) 309–311

    Language English
    Publishing date 2021-12-07
    Publishing country India
    Document type Journal Article
    ZDB-ID 2240174-X
    ISSN 1998-3549 ; 0972-2327
    ISSN (online) 1998-3549
    ISSN 0972-2327
    DOI 10.4103/aian.aian_401_21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Carbamazepine-induced Seizure in a Nonepileptic Child.

    Benny, Rajesh / Bolegave, Vyankatesh / Sadavarte, Sameer / Khatav, Vinayak

    Annals of Indian Academy of Neurology

    2017  Volume 20, Issue 4, Page(s) 432–434

    Language English
    Publishing date 2017-10-03
    Publishing country India
    Document type Journal Article
    ZDB-ID 2240174-X
    ISSN 1998-3549 ; 0972-2327
    ISSN (online) 1998-3549
    ISSN 0972-2327
    DOI 10.4103/aian.AIAN_169_17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Cerebral Venous Thrombosis in COVID-19.

    Benny, Rajesh / Singh, Rakeshsingh K / Venkitachalam, Anil / Lalla, Rakesh S / Shah, Amit M / Bolegave, Vyankatesh / Shetty, Ashutosh N / Panchal, Keyur C / Choudhary, Jitendra / Mathew, Anita / Hunnur, Manoj / Shetty, Kishore V

    Neurology India

    2022  Volume 70, Issue 2, Page(s) 652–659

    Abstract: Background: COVID-19 causes a hypercoagulable state leading to thrombosis. Many of these thrombotic complications occur in those with severe disease and late in the disease course. COVID-19 has recently been associated with cerebral venous thrombosis ( ... ...

    Abstract Background: COVID-19 causes a hypercoagulable state leading to thrombosis. Many of these thrombotic complications occur in those with severe disease and late in the disease course. COVID-19 has recently been associated with cerebral venous thrombosis (CVT).
    Objective: To study the onset of CVT in relation to COVID-19 and compare their characteristics and outcomes with non-COVID CVT patients admitted during the same period.
    Materials and methods: This multicentric, retrospective study conducted between April 4 and October 15, 2020, included adult patients with CVT who were positive for the SARS-CoV-2 virus and compared them with CVT patients who were negative for the SARS-CoV-2 virus hospitalized during the same period. We studied their clinical profile, risk factors for CVT, and markers of COVID coagulopathy, imaging characteristics, and factors influencing their outcomes.
    Results: We included 18 COVID-19-infected patients and compared them with 43 non-COVID-19 CVT patients. Fourteen patients in the COVID-19 group presented with CVT without the other typical features of COVID-19. Thirteen patients had non-severe COVID-19 disease. Twelve patients had a good outcome (mRS ≤2). Mortality and disability outcomes were not significantly different between the two groups.
    Conclusion: Our study suggests a possible association between COVID-19 and CVT. CVT can be the presenting manifestation of an underlying COVID-19, occurring early in the course of COVID-19 and even in those with mild disease. Patients with worse GCS on admission, abnormal HRCT chest, severe COVID-19, and need for invasive ventilation had a poor outcome.
    MeSH term(s) Adult ; COVID-19/complications ; Humans ; Intracranial Thrombosis/complications ; Retrospective Studies ; SARS-CoV-2 ; Venous Thrombosis/etiology
    Language English
    Publishing date 2022-05-09
    Publishing country India
    Document type Journal Article ; Multicenter Study
    ZDB-ID 415522-1
    ISSN 1998-4022 ; 0028-3886
    ISSN (online) 1998-4022
    ISSN 0028-3886
    DOI 10.4103/0028-3886.344623
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Cerebrovascular Involvement in Mucormycosis in COVID-19 Pandemic.

    Kulkarni, Rahul / Pujari, Shripad S / Gupta, Dulari / Ojha, Pawan / Dhamne, Megha / Bolegave, Vyankatesh / Dhonde, Pramod / Soni, Anand / Adwani, Sikandar / Diwan, Anand / Duberkar, Dhananjay / Batra, Dhruv / Deshpande, Rushikesh / Aurangabadkar, Kaustubh / Palasdeokar, Nilesh

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

    2021  Volume 31, Issue 2, Page(s) 106231

    Abstract: Background: Many countries have seen an unprecedented rise of cases of coronavirus disease 2019 (COVID-19) associated mucormycosis (CAM). Cerebrovascular involvement in CAM has not been studied so far. We describe clinico-radiological manifestations of ... ...

    Abstract Background: Many countries have seen an unprecedented rise of cases of coronavirus disease 2019 (COVID-19) associated mucormycosis (CAM). Cerebrovascular involvement in CAM has not been studied so far. We describe clinico-radiological manifestations of cerebrovascular complications observed in CAM.
    Methods: In this multicentric retrospective observational study from India, patients with CAM who developed cerebrovascular involvement were studied. Their demographics, risk factors, clinical manifestations, imaging, laboratory profile and outcomes were noted.
    Results: Out of 49 subjects with cerebrovascular involvement, 71.4% were males while average age was 52.9 years. Ischemic stroke was commonest (91.8%) followed by intracranial haemorrhage (6.1%) and subarachnoid haemorrhage (2%). The incidence of cerebrovascular complications in CAM was found to be 11.8% in one center. Cerebrovascular symptoms appeared a median of 8.3 days from the onset of mucormycosis. Commonest presentation of mucormycosis was rhino-orbito-cerebral syndrome in 98%. Diabetes mellitus was present in 81.7%. Forty percent developed stroke despite being on antiplatelet agent and/or heparin. Amongst subjects with ischemic strokes, location of stroke was unilateral anterior circulation (62.2%); bilateral anterior circulation (17.8%); posterior circulation (11.1%) and combined anterior and posterior circulation (8.9%). Vascular imaging revealed intracranial occlusion in 62.1%; extracranial occlusion in 3.4% and normal vessels in 34.5%. Mortality was 51% during hospital stay.
    Conclusions: Cerebrovascular involvement was seen in 11.8% patients of CAM. Angio-invasive nature of the fungus, prothrombotic state created by COVID-19, and diabetes were important causative factors. Subjects with CAM should be screened for involvement of the brain as well as its vessel. Antiplatelet agents/heparin did not seem to provide complete protection from this type of stroke.
    MeSH term(s) Adult ; Aged ; COVID-19/complications ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19 Testing ; Cerebrovascular Disorders/complications ; Cerebrovascular Disorders/epidemiology ; Female ; Humans ; Incidence ; India/epidemiology ; Male ; Middle Aged ; Mucormycosis/complications ; Mucormycosis/diagnosis ; Mucormycosis/epidemiology ; Pandemics ; Retrospective Studies ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2/genetics ; SARS-CoV-2/isolation & purification ; Stroke/epidemiology
    Language English
    Publishing date 2021-11-22
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 1131675-5
    ISSN 1532-8511 ; 1052-3057
    ISSN (online) 1532-8511
    ISSN 1052-3057
    DOI 10.1016/j.jstrokecerebrovasdis.2021.106231
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Guillian--Barre' Syndrome in Patients with SARS-CoV-2: A Multicentric Study from Maharashtra, India.

    Dhamne, Megha C / Benny, Rajesh / Singh, Rakesh / Pande, Amitkumar / Agarwal, Pankaj / Wagh, Satish / Oak, Pradyumna / Lakhotia, Akshay / Godge, Yogesh / Bolegave, Vyankatesh / Doshi, Darshan / Patidar, Yogesh / Venkatachalam, Anil / Pujara, Bhavin / Borse, Sandeep / Makhija, Prashant / Khadilkar, Satish

    Annals of Indian Academy of Neurology

    2021  Volume 24, Issue 3, Page(s) 339–346

    Abstract: Background: Guillian--Barre' Syndrome (GBS) has been shown to be associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The aim of our study was to study the clinical profile and outcomes of GBS in COVID-19 from the ... ...

    Abstract Background: Guillian--Barre' Syndrome (GBS) has been shown to be associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The aim of our study was to study the clinical profile and outcomes of GBS in COVID-19 from the Western region of India, the State of Maharashtra.
    Methods: This was a retrospective, multicenter observation study from different hospitals in Maharashtra beginning from March 2020 until November 2020.
    Results: We report 42 patients with COVID-19 GBS. Mean age was 59 years (range, 24--85 years). 31/42 (73.8%) were men. GBS was the presenting symptom in 14/42 (33%), while six of them remained asymptomatic for COVID-19 despite positive SARS-CoV-2 on nasopharyngeal swab reverse transcriptase polymerase chain reaction. The median interval between COVID-19 and GBS was 14 days (SD + 11), with minimum of 1 and maximum 40 days. Clinical presentation was like that of typical GBS. Electrophysiological studies showed a predominant demyelinating pattern in 25/42 (59.5%). Inflammatory markers were elevated in 35/42 (83.3%) and 38/42 (90.5%) had an Abnormal high-resolution CT (HRCT) chest. 14/42 (33.3%) patients required a ventilator, with nine deaths. Intravenous immunoglobulin was the mainstay of treatment for GBS. Majority had a good outcome and were walking independently or with minimal support at discharge. In subgroup analysis, the postinfectious group had a better outcome than the parainfectious group.
    Conclusion: GBS in COVID-19 occurs as both parainfectious and postinfectious GBS. Parainfectious GBS needs more rigorous monitoring and may benefit from COVID-19 specific treatment. Routine screening for SARS-CoV-2 should be implemented in patients with GBS in view of the ongoing pandemic.
    Language English
    Publishing date 2021-07-09
    Publishing country India
    Document type Journal Article
    ZDB-ID 2240174-X
    ISSN 1998-3549 ; 0972-2327
    ISSN (online) 1998-3549
    ISSN 0972-2327
    DOI 10.4103/aian.AIAN_1303_20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Characteristics and outcomes of 100 consecutive patients with acute stroke and COVID-19.

    Benny, Rajesh / Singh, Rakeshsingh K / Venkitachalam, Anil / Lalla, Rakesh Shyam / Pandit, Rahul A / Panchal, Keyur C / Pardasani, Vibhor / Chanchalani, Gunjan / Basle, Mheboob / Bolegave, Vyankatesh / Manoj, Hunnur / Shetty, Ashutosh N / Shah, Amit M / Pai, Pawan / Banthia, Nilesh M / Patil, Shekhar G / Chafale, Vishal / Pujara, Bhavin / Shah, Sanjay /
    Mehta, Naresh / Thakkar, Vicky V / Patel, Vikas / Shetty, Kishore V

    Journal of the neurological sciences

    2021  Volume 423, Page(s) 117348

    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Brain Ischemia/complications ; Brain Ischemia/drug therapy ; Brain Ischemia/therapy ; COVID-19/complications ; COVID-19 Testing ; Comorbidity ; Female ; Fibrinolytic Agents/therapeutic use ; Glasgow Coma Scale ; Headache/epidemiology ; Heart Disease Risk Factors ; Humans ; Male ; Mechanical Thrombolysis ; Middle Aged ; SARS-CoV-2 ; Sensation Disorders/epidemiology ; Stroke/complications ; Stroke/drug therapy ; Stroke/surgery ; Symptom Assessment ; Thrombolytic Therapy ; Time-to-Treatment ; Tissue Plasminogen Activator/therapeutic use ; Treatment Outcome
    Chemical Substances Fibrinolytic Agents ; Tissue Plasminogen Activator (EC 3.4.21.68)
    Language English
    Publishing date 2021-02-17
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 80160-4
    ISSN 1878-5883 ; 0022-510X ; 0374-8642
    ISSN (online) 1878-5883
    ISSN 0022-510X ; 0374-8642
    DOI 10.1016/j.jns.2021.117348
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Rhino-Orbito-Cerebral Mycosis and COVID-19: From Bad to Worse?

    Kulkarni, Rahul / Pujari, Shripad / Gupta, Dulari / Advani, Sikandar / Soni, Anand / Duberkar, Dhananjay / Dhonde, Pramod / Batra, Dhruv / Bilala, Saurabh / Agrawal, Preetesh / Aurangabadkar, Koustubh / Jain, Neeraj / Shetty, Kishorekumar / Dhamne, Megha / Bolegave, Vyankatesh / Patidar, Yogesh / More, Aniruddha / Nirhale, Satish / Rao, Prajwal /
    Pande, Amitkumar / Doshi, Suyog / Chauvhan, Aradhana / Palasdeokar, Nilesh / Valzade, Priyanka / Jagtap, Sujit / Deshpande, Rushikesh / Patwardhan, Sampada / Purandare, Bharat / Prayag, Parikshit

    Annals of Indian Academy of Neurology

    2021  Volume 25, Issue 1, Page(s) 68–75

    Abstract: Background: There has been an increase an alarming rise in invasive mycoses during COVID-19 pandemic, especially during the second wave.: Aims: Compare the incidence of invasive mycoses in the last three years and study the risk factors, ... ...

    Abstract Background: There has been an increase an alarming rise in invasive mycoses during COVID-19 pandemic, especially during the second wave.
    Aims: Compare the incidence of invasive mycoses in the last three years and study the risk factors, manifestations and outcomes of mycoses in the COVID era.
    Methodology: Multicentric study was conducted across 21 centres in a state of western India over 12-months. The clinico-radiological, laboratory and microbiological features, treatment and outcomes of patients were studied. We also analysed yearly incidence of rhino-orbito-cerebral mycosis.
    Results: There was more than five-times rise in the incidence of invasive mycoses compared to previous two-years. Of the 122 patients analysed, mucor, aspergillus and dual infection were seen in 86.9%, 4.1%, and 7.4% respectively. Fifty-nine percent had simultaneous mycosis and COVID-19 while rest had sequential infection. Common presenting features were headache (91%), facial pain (78.7%), diplopia (66.4%) and vison loss (56.6%). Rhino-orbito-sinusitis was present in 96.7%, meningitis in 6.6%, intracranial mass lesions in 15.6% and strokes in 14.8%. A total of 91.8% patients were diabetic, while 90.2% were treated with steroids during COVID-19 treatment. Mortality was 34.4%.
    Conclusion: Invasive fungal infections having high mortality and morbidity have increased burden on already overburdened healthcare system. Past illnesses, COVID-19 itself and its treatment and environmental factors seem responsible for the rise of fungal infection. Awareness and preventive strategies are the need of hours and larger studies are needed for better understanding of this deadly disease.
    Language English
    Publishing date 2021-08-23
    Publishing country India
    Document type Journal Article
    ZDB-ID 2240174-X
    ISSN 1998-3549 ; 0972-2327
    ISSN (online) 1998-3549
    ISSN 0972-2327
    DOI 10.4103/aian.aian_463_21
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top